The global Amyloidosis Treatment Market size is expected to reach USD 6.7 billion by
2025, according to a new report by Grand View Research, Inc., registering a
7.2% CAGR during the forecast period. Several factors such as increased
adoption of novel targeted therapies and transplantations, emergence of
biologics, and rising geriatric population are driving the market.
Amyloidosis is a group of rare
diseases where misfolded aggregates of proteins (amyloids) buildup in tissues
and organs. AL amyloidosis is the most common type of amyloidosis in U.S., with
approximately 3,000 to 4,000 new cases diagnosed annually. Although in majority
of cases, the disease is diagnosed in people over the age of 60, there are a
few cases of people being diagnosed in their late 20s and about two-thirds of
the patients are male.
Among treatments, chemotherapy
held the largest share in 2017, followed by targeted therapy, and supportive
care. However, targeted therapies are expected to dominate the market in 2025,
supported by a strong pipeline and potential approval of drugs such as
Alnylam’s Onpattro, Ionis’ Tegsedi, Johnson & Johnson’s Darzalex, and
Takeda’s Ninlaro.
Stem cell transplants and
targeted therapies are gaining traction in developed countries. However,
amyloidosis cohorts in endemic regions do not have access to sufficient
healthcare infrastructure to ensure prompt diagnosis and treatment in
underdeveloped countries. Chemotherapy and supportive care are anticipated to
lose market share over the forecast period due to adverse side effects and
lower efficacy.
Further key findings from the report suggest:
- An estimated 16,000 people in U.S. suffer from
amyloidosis, with approximately 3,000 to 4,000 new cases being reported
annually
- U.S. dominated the global amyloidosis treatment
market, with a share of more than 27.0% in 2017 due to potential launch of
pipeline drugs, increased adoption of novel therapeutics, and high cost of
treatment in the country
- Chemotherapy dominated the amyloidosis
treatment market, with a share of about 35.0% in 2017. Targeted therapies
are projected to witness double-digit growth during the forecast period
due to multiple product approvals
- Emerging markets for amyloidosis such as China,
Sweden, Portugal, Turkey, South Africa, Brazil, Mexico, Saudi Arabia, and
India are expected to show attractive growth over the forecast period due
to improved healthcare infrastructure, favorable government policies,
increased investment, and large amyloidosis cohort
- Alnylam, Ionis, Pfizer, Johnson & Johnson
and Takeda are some of the key players operating in this market
- Currently, 19 products are under evaluation for
amyloidosis treatment in various stages of clinical development. Promising
pipeline candidates such as Onpattro, Vyndaqel, Tegsedi, Darzalex, and
Ninlaro are expected to generate significant revenue upon launch.
Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/amyloidosis-treatment-market
No comments:
Post a Comment